Literature DB >> 16020995

Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-American population.

Errol D Crook1, Daniel Habeeb, Otis Gowdy, Santhi Nimmagadda, Mahmoud Salem.   

Abstract

BACKGROUND: Focal segmental glomerulosclerosis (FSGS) is a common primary glomerulopathy in African Americans. Prolonged treatment with steroids is recommended for FSGS in those with nephrotic-range proteinuria, but strong evidence for this recommendation, especially in African-American adults, is lacking. We reviewed our experience with steroids in FSGS in a predominantly African-American cohort.
METHODS: Patients with primary FSGS were identified and their charts were retrospectively reviewed for demographic data, characteristics of renal biopsy, blood pressure, and use of steroids. End-stage renal disease and doubling of creatinine were end-points.
RESULTS: Seventy-two patients (65 African Americans) were identified with 48.3 months of follow-up. Patients receiving steroids (n=43) had higher urine protein excretion than those who did not. Seventeen patients reached end-stage renal disease and 26 doubled their creatinine concentration. Factors significant for renal survival on Cox proportional hazards model were initial creatinine level, severity of renal lesion, and blood pressure over the follow-up period. Treatment with steroids did not affect renal survival. About one third of patients receiving steroids developed complications consisting of diabetes (n=4) and greater than 5 kg weight gain (n=10).
CONCLUSION: Renal function, severity of the renal lesion, and blood pressure determine renal survival in FSGS. A beneficial effect of steroids was not observed in this predominantly African-American adult cohort.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020995     DOI: 10.1097/00000441-200507000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  6 in total

1.  Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Authors:  Monique E Cho; Mary H Branton; David A Smith; Linda Bartlett; Lilian Howard; James C Reynolds; Donald Rosenstein; Sanjeev Sethi; M Berenice Nava; Laura Barisoni; Fernando C Fervenza; Jeffrey B Kopp
Journal:  Am J Nephrol       Date:  2019-04-09       Impact factor: 3.754

2.  Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations.

Authors:  Sanjeev Sethi; Ladan Zand; Samih H Nasr; Richard J Glassock; Fernando C Fervenza
Journal:  Clin Kidney J       Date:  2014-09-28

3.  Calcineurin inhibitors in the treatment of primary focal segmental glomerulosclerosis: A protocol of systematic review and meta-analysis of randomized controlled trials.

Authors:  Guozhong Xue; Xinbin Wang; Shuwen Li; Enlai Dai
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

4.  Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis.

Authors:  Dawn J Caster; Barbara Magalhaes; Natali Pennese; Andrea Zaffalon; Marina Faiella; Kirk N Campbell; Jai Radhakrishnan; Vladmir Tesar; Howard Trachtman
Journal:  Kidney Med       Date:  2022-06-11

5.  Angiotensin-converting enzyme gene polymophism in adult primary focal segmental glomerulosclerosis.

Authors:  Rozita Mohd; Zaimi Abdul Wahab; Rizna Cader; Halim A Gafor; Azizah Md Radzi; Shamsul Azhar Shah; Norella Kong Chiew Tong
Journal:  J Clin Med Res       Date:  2014-05-22

6.  A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Authors:  Flavio Vincenti; Fernando C Fervenza; Kirk N Campbell; Montserrat Diaz; Loreto Gesualdo; Peter Nelson; Manuel Praga; Jai Radhakrishnan; Lorenz Sellin; Ajay Singh; Denyse Thornley-Brown; Francisco Veríssimo Veronese; Beverly Accomando; Sara Engstrand; Steven Ledbetter; Julie Lin; John Neylan; James Tumlin
Journal:  Kidney Int Rep       Date:  2017-04-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.